NCT05499416View on ClinicalTrials.gov

Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2023

Primary Completion Date

September 30, 2023

Study Completion Date

April 30, 2024

Conditions
Psoriasis VulgarisActive Psoriatic Arthritis
Interventions
DRUG

Bimekizumab

Self-administration of two (2-160 mg/mL \[1 mL\]) pre-filled syringes or autoinjectors at baseline (Day1) and at Weeks 4, 8,12, and 16

Sponsors
All Listed Sponsors
collaborator

Ciusss de L'Est de l'Île de Montréal

OTHER

lead

Innovaderm Research Inc.

OTHER